6 unknown. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Unknown 6 |
| Phase 2 | 1 | Unknown 1 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema Conestat Alfa - ACE Inhibitor-Induced Angioedema | Phase 3 | Unknown | University of Cincinnati | 24 | 2024-12-01 | 2024-11-07 |
| Using Doxepin for Urticaria Doxepin, Diphenhydramine - Urticaria | Phase 3 | Unknown | State University of New York - Upstate Medical University | 160 | 2022-05-23 | 2022-05-18 |
| Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria SYN008, Omalizumab for injection - Chronic Spontaneous Urticaria | Phase 3 | Unknown | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 340 | 2021-07-01 | 2021-06-29 |
| Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria Recombinant human interleukin-2 (rhIL-2), Control group - Chronic Spontaneous Urticaria | Phase 2 / Phase 3 | Unknown | Second Xiangya Hospital of Central South University | 56 | 2021-06-16 | 2021-05-20 |
| High Dose Vitamin D Supplementation in Chronic Spontaneous Urticaria Vitamin D3 (High dose), Vitamin D3 (Low dose) - Urticaria | Phase 3 | Unknown | Shiraz University of Medical Sciences | 80 | 2016-08-01 | 2016-08-19 |
| Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria Omalizimab - Chronic Idiopathic Urticaria | Phase 3 | Unknown | Rabin Medical Center | 20 | 2014-07-01 | 2014-06-18 |
Chronic Urticaria (3) · Angioedema (1)
Hypersensitivity (6) · Hypersensitivity, Immediate (6) · Immune System Diseases (6) · Skin Diseases (6) · Skin Diseases, Vascular (6) · Skin and Connective Tissue Diseases (6) · Chronic Disease (3) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Cardiovascular Diseases (1) · Vascular Diseases (1)
Omalizumab (2) · Cholecalciferol (1) · Control Groups (1) · Diphenhydramine (1) · Doxepin (1) · Injections (1) · aldesleukin (1) · conestat alfa (1)
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (1) · Rabin Medical Center (1) · Second Xiangya Hospital of Central South University (1) · Shiraz University of Medical Sciences (1) · State University of New York - Upstate Medical University (1) · University of Cincinnati (1)
China (1) · Iran (1) · Israel (1) · United States (1)
Gentry Wilkerson, MD (1) · Joseph A. Moellman, MD (1) · Keramatallah Jahanshahi, MD (1) · Michael David, Prof (1) · Qianjin Lu, MD, PhD (1) · Ruo-Yu Li (1)